The Generative Brain

Gate Bioscience oral small-molecule Molecular Gate

Gate Bioscience is developing an oral, brain-penetrant small molecule that stops cells from exporting PrP and sends it for destruction, with the goal of a pill that lowers brain PrP. The only data in view come from the company, its foundation grant and conference reports: an 80 percent fall in mouse brain PrP after about a week of daily dosing, and a conference excerpt saying survival was extended in infected mice. No peer-reviewed data paper, regulatory filing or human data were found.

Key facts

  • Mechanism in plain terms: a Molecular Gate is an oral small molecule that blocks a target protein's exit from the cell, in the company's description by blocking passage through the Sec61 secretory channel, so the protein is degraded instead of secreted; for prion disease the aim is to cut the amount of PrP in the brain.
  • Developer: Gate Bioscience, a California biotechnology company; Nina Oberbeck, senior director of translational sciences, leads its prion program and has presented the work at Prion 2024 and the 2023 national CJD conference.
  • Collaboration: the Broad Institute's Vallabh Minikel lab has collaborated with Gate since 2021, and the 2025 grant funds the lab to help test survival in a prion mouse model.
  • Funding: a 2025 CJD Foundation research grant on assessing efficacy of a PrP-lowering Molecular Gate, supported by named family memorial grants and the Strides for CJD fund.
  • Company funding: a USD 65 million Series B in November 2025 led by Forbion with Eli Lilly joining, bringing total capital to USD 135 million, to fund IND-enabling studies and Phase 1 for lead programs in inflammatory and neurological disease; the release does not name prion disease.
  • Mouse PrP lowering: in the grant description, a lead compound lowered mouse brain PrP by 80 percent after a week of once-daily dosing; a Prion 2024 abstract excerpt gives 100 mg per kg by mouth for 8 days with brain PrP down 80 percent and colon PrP down 96 percent versus vehicle (excerpt only).
  • Survival evidence: a Prion 2025 meeting report excerpt says MG-813 lowered PrP in cells and extended survival in prion-infected mice dosed chronically after symptom onset; no numbers were seen and the page could not be opened, so treat this as unverified.
  • Stage statement from the company side: Gate's prion therapeutic is described as in preclinical development and not yet ready for clinical trials.
  • Context for time to effect: 2026 work from the Minikel group estimates a 5 to 6 day half-life for PrP in mouse brain and finds colon PrP measurable, bearing on how fast an oral PrP-lowering drug could act; Gate supported that paper and a Gate scientist is an author; it does not test a Molecular Gate.
  • Human data: none found; no trial registry entry, IND statement or primate data found.
  • Separate commercial context: Gate has a discovery deal with Eli Lilly described by a trade source as worth up to USD 856 million, not specific to prion disease.

Timeline

  1. 2021Gate and the Broad Vallabh Minikel lab begin collaborating.
  2. 2023Oberbeck presents Gate's prion work at the national CJD conference in Melbourne.
  3. 2024Prion 2024 meeting abstract reports oral MG-813 lowering mouse brain PrP by 80 percent (excerpt only).
  4. 2025CJD Foundation publishes the 2025 grant record for the survival study.
  5. 2025Gate announces a USD 65 million Series B.
  6. 2026PLOS Pathogens paper on PrP turnover, with Gate support, appears.
Sources for this page